Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis
SUJIT NAYEK, Nulgumnalli Manjunathaiah Raghavendra, B. Sajeev Kumar
Journal of Drug Delivery Science and Technology (2020) Vol. 61, pp. 102073-102073
Closed Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Nanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management
Priti Tagde, Agnieszka Najda, Kalpana Nagpal, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2856-2856
Open Access | Times Cited: 96
Design, synthesis, and in-Silco ADME prediction of some novel bis(1,3,4-thiadiazoles) encapsulated lipid chitosan nano capsule decorative with magnetic nanoparticles and their potential anti-helicobacter pylori activity
Mostafa E. Salem, Ahmed H. M. Elwahy, Hamdi M. Hassaneen, et al.
International Journal of Biological Macromolecules (2025), pp. 139746-139746
Closed Access | Times Cited: 1
Mucin-1 conjugated polyamidoamine-based nanoparticles for image-guided delivery of gefitinib to breast cancer
Poorya Najjari Nabi, Nasim Vahidfar, Mohammad Reza Tohidkia, et al.
International Journal of Biological Macromolecules (2021) Vol. 174, pp. 185-197
Closed Access | Times Cited: 43
Chitosan nanoparticles as a smart nanocarrier for gefitinib for tackling lung cancer: Design of experiment and in vitro cytotoxicity study
Haitham Amin, Mohammed A. Amin, Shaaban K. Osman, et al.
International Journal of Biological Macromolecules (2023) Vol. 246, pp. 125638-125638
Closed Access | Times Cited: 21
Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer
Abdelrahman Y. Sherif, Gamaleldin I. Harisa, Ahmad Abdul-Wahhab Shahba, et al.
Molecules (2023) Vol. 28, Iss. 1, pp. 448-448
Open Access | Times Cited: 20
Drug delivery systems of gefitinib for improved cancer therapy: A review
Deepak Nagdiya, Manish Kumar, Sanchit Arora, et al.
OpenNano (2023) Vol. 14, pp. 100183-100183
Open Access | Times Cited: 13
Gefitinib salts/cocrystals with phenolic acids as a promising solid-state approach to improve solubility
Y. Zou, Xin Meng, Baoxi Zhang, et al.
CrystEngComm (2024) Vol. 26, Iss. 15, pp. 2112-2122
Closed Access | Times Cited: 5
PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer
Abdelrahman Y. Sherif, Gamaleldin I. Harisa, Fars K. Alanazi, et al.
International Journal of Nanomedicine (2022) Vol. Volume 17, pp. 3287-3311
Open Access | Times Cited: 22
Gefitinib: An Updated Review of its Role in the Cancer Management, its Nanotechnological Interventions, Recent Patents and Clinical Trials
Pankaj Kumar, Bharti Mangla, Shamama Javed, et al.
Recent Patents on Anti-Cancer Drug Discovery (2022) Vol. 18, Iss. 4, pp. 448-469
Closed Access | Times Cited: 20
A comprehensive review on nanocarriers as a targeted delivery system for the treatment of breast cancer
Amreen Fatima, Nazish Naseem, Md. Faheem Haider, et al.
Intelligent Pharmacy (2024) Vol. 2, Iss. 3, pp. 415-426
Open Access | Times Cited: 4
HER-2 Receptor and αvβ3 Integrin Dual-Ligand Surface-Functionalized Liposome for Metastatic Breast Cancer Therapy
Dilip Kumar Arya, Hemali Deshpande, Ashish Kumar, et al.
Pharmaceutics (2024) Vol. 16, Iss. 9, pp. 1128-1128
Open Access | Times Cited: 4
Soluble starch nanoparticles loaded with Gefitinib for treating lung cancer: Optimization and cytotoxicity assessment
Mohammed A. Amin, Hamdoon A. Mohammed
International Journal of Biological Macromolecules (2025), pp. 140369-140369
Closed Access
Development of PLGA-SPC3 functionalized Gefitinib mesoporous silica nano-scaffolds for breast cancer targeting: Biodistribution and Cytotoxicity analysis
Renu Sah, Sajeev KumarB
Pharmaceutical Development and Technology (2025), pp. 1-26
Closed Access
Nanotechnology-based drug delivery for breast cancer treatment: Current applications and future directions
Md Abdus Samad, Iftikhar Ahmad, Torki A. Zughaibi, et al.
European Journal of Medicinal Chemistry Reports (2025), pp. 100268-100268
Open Access
Formulation, In Vitro and In Vivo Evaluation of Gefitinib Solid Dispersions Prepared Using Different Techniques
Sultan Alshehri, Abdullah Alanazi, Ehab M. Elzayat, et al.
Processes (2021) Vol. 9, Iss. 7, pp. 1210-1210
Open Access | Times Cited: 25
Gefitinib-loaded starch nanoparticles for battling lung cancer: Optimization by full factorial design and in vitro cytotoxicity evaluation
Haitham Amin, Shaaban K. Osman, Ahmed Mohammed, et al.
Saudi Pharmaceutical Journal (2022) Vol. 31, Iss. 1, pp. 29-54
Open Access | Times Cited: 18
Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line
Abdelrahman Y. Sherif, Gamaleldin I. Harisa, Fars K. Alanazi, et al.
AAPS PharmSciTech (2022) Vol. 23, Iss. 6
Open Access | Times Cited: 15
Fabrication of D-α-tocopheryl polyethylene glycol 1000 succinates and human serum albumin conjugated chitosan nanoparticles of bosutinib for colon targeting application; in vitro-in vivo investigation
Laxmi Manthalkar, Sankha Bhattacharya, Ketan Hatware, et al.
International Journal of Biological Macromolecules (2023) Vol. 253, pp. 127531-127531
Closed Access | Times Cited: 9
TPGS decorated NLC shift gefitinib from portal absorption into lymphatic delivery: Intracellular trafficking, biodistribution and bioavailability studies
Gamaleldin I. Harisa, Abdelrahman Y. Sherif, Fars K. Alanazi, et al.
Colloids and Surfaces B Biointerfaces (2023) Vol. 223, pp. 113148-113148
Closed Access | Times Cited: 8
A comprehensive review on lipid nanocarrier systems for cancer treatment: fabrication, future prospects and clinical trials
Mohamed Fawzi Kabil, Osama A. Badary, Frank F. Bier, et al.
Journal of Liposome Research (2023) Vol. 34, Iss. 1, pp. 135-177
Closed Access | Times Cited: 8
Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles
Ehab M. Elzayat, Abdelrahman Y. Sherif, Fahd A. Nasr, et al.
Materials (2023) Vol. 16, Iss. 15, pp. 5364-5364
Open Access | Times Cited: 8
Applications of lipid-engineered nanoplatforms in the delivery of various cancer therapeutics to surmount breast cancer
Ujala Gupta, Brojendra Nath Saren, Kedar Khaparkhuntikar, et al.
Journal of Controlled Release (2022) Vol. 348, pp. 1089-1115
Closed Access | Times Cited: 14
Design, synthesis of some novel coumarins and their nanoformulations into lipid-chitosan nanocapsule as unique antimicrobial agents
Ibrahim Taha Radwan, Ibrahim M. El‐Sherbiny, Abdelfattah Selim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
The Chimera of TPGS and Nanoscale Lipid Carriers as Lymphatic Drug Delivery Vehicles to Fight Metastatic Cancers
Abdelrahman Y. Sherif, Gamaleldin I. Harisa, Fars K. Alanazi
Current Drug Delivery (2023) Vol. 21, Iss. 4, pp. 525-543
Closed Access | Times Cited: 5
Innovative lipid nanoparticles: A cutting-edge approach for potential renal cell carcinoma therapeutics
Asif Shahzad, Zhuoran Teng, Muhammad Arfat Yameen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117465-117465
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top